Head to head
CJC-1295 against Modified GRF 1-29
These are sold as two versions of one product, with and without DAC. They are not two versions of one product, and the trial data everyone quotes belongs to only one of them.
Column A
CJC-1295CJC-1295 (GHRH analogue)
A modified GHRH analogue engineered for an extended half-life, promoting sustained growth hormone and IGF-1 release.
Column B
Modified GRF 1-29Modified GRF 1-29, tetrasubstituted human growth hormone releasing factor 1-29
Sold as CJC-1295 without DAC, which is a contradiction: the DAC is what makes a molecule CJC-1295. The human trial everyone quotes, 2 to 10 fold higher growth hormone for 6 days or more with a half-life of 5.8 to 8.1 days, was run on the DAC form. No human trial of the version without the DAC has been located.
The mistake this page exists to correct
Modified GRF 1-29 is routinely labelled CJC-1295 without DAC, which is a contradiction in terms: the drug affinity complex is the modification that makes a molecule CJC-1295. The human result quoted for both, growth hormone raised two to ten fold for six days or more with a half-life of 5.8 to 8.1 days, was produced with the DAC form. No human trial of the version without DAC has been located. A half-life measured in days and a half-life measured in minutes do not support the same dosing schedule, and they are not the same molecule.
Side by side, on the facts we can check
| Attribute | CJC-1295 | Modified GRF 1-29 |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA status | Not FDA-approved | Not approved for any indication and not evaluated. Sermorelin, the unmodified GRF 1-29, was an approved medicine in the United States and is no longer marketed in its original form. Tesamorelin, a different GHRH analogue, is approved for HIV-associated lipodystrophy. |
| Half-life | ~6-8 days (DAC version) | Not measured in humans for this compound. For scale, native GRF 1-29 is cleared within minutes, while the albumin-bound DAC version was measured at about 6 days in healthy adults. |
| Molecular weight | 3,647.2 Da | About 3,368 Da for the tetrasubstituted 29 amino acid peptide without the DAC maleimide. |
| Mechanism | Activates the GHRH receptor on the pituitary to increase growth hormone secretion; albumin binding prolongs its activity. | A growth hormone releasing hormone analogue acting at the GHRH receptor on anterior pituitary somatotrophs to trigger growth hormone release, which raises IGF-1 downstream. The tetrasubstitution of the native GRF 1-29 sequence resists dipeptidyl peptidase IV cleavage, extending the peptide's survival in plasma from minutes to somewhat longer, but it does not confer albumin binding. Release stays pulsatile and dependent on the pituitary's own capacity and on the opposing somatostatin tone, which is the practical difference between a secretagogue and injected growth hormone. |
| Human studies cited | 2 | 2 |
| Legal status, US | Not approved; research use only | Not approved; research use only |
Frequently asked questions
What is the difference between CJC-1295 and Modified GRF 1-29?
CJC-1295: A modified GHRH analogue engineered for an extended half-life, promoting sustained growth hormone and IGF-1 release. Modified GRF 1-29: Sold as CJC-1295 without DAC, which is a contradiction: the DAC is what makes a molecule CJC-1295. The human trial everyone quotes, 2 to 10 fold higher growth hormone for 6 days or more with a half-life of 5.8 to 8.1 days, was run on the DAC form. No human trial of the version without the DAC has been located.
Which has stronger research evidence, CJC-1295 or Modified GRF 1-29?
This database does not grade compounds. It counts what was run in people: 2 of the 2 studies cited on the CJC-1295 profile were human work, against 2 of 5 for Modified GRF 1-29. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are CJC-1295 and Modified GRF 1-29 FDA-approved?
CJC-1295: Not FDA-approved. Modified GRF 1-29: Not approved for any indication and not evaluated. Sermorelin, the unmodified GRF 1-29, was an approved medicine in the United States and is no longer marketed in its original form. Tesamorelin, a different GHRH analogue, is approved for HIV-associated lipodystrophy..
Related posts
Blog articles that cover CJC-1295 or Modified GRF 1-29, newest first.
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.